Ocular Therapeutix is a biopharmaceutical company. Co. commercializes two products in the U.S.: DEXTENZA®, an intracanalicular insert for the treatment of both post-surgical ocular inflammation and pain and ocular itching associated with allergic conjunctivitis, and ReSure Sealant, an ophthalmic device designed to prevent wound leaks in corneal incisions following cataract surgery. Co. also has product candidates in preclinical and clinical development designed to utilize its bioresorbable hydrogel technology to treat retinal diseases including wet age-related macular degeneration; glaucoma and ocular hypertension; and ocular surface diseases and conditions including dry eye disease. The OCUL average annual return since 2014 is shown above.
The Average Annual Return on the OCUL average annual return since 2014 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether OCUL average annual return since 2014 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the OCUL average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|